Mouse models of asthma: Can they give us mechanistic insights into the role of nitric oxide?

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

New clinical practice guidelines for patients with asthma include the recommendation to monitor exhaled breath nitric oxide (NO) levels. NO concentrations in exhaled breath are increased in asthmatics and increased NO levels correlate with worsening airway inflammation and asthma symptoms. The multiple roles of NO in the lung have not been delineated clearly. Clinical trials are being performed presently that test the apparently conflicting hypotheses that either donors or inhibitors of NO in the lung are effective strategies for treating asthma. These strategies evolved, in part, from results of pre-clinical studies performed in mice and other animal models. This review evaluates the existing literature with regard to mouse models of asthma and explores the often conflicting data on the role of NO, the nitric oxide synthase (NOS) enzymes, and the arginase enzymes in allergic airway inflammation. While we will emphasize the ovalbumin exposure mouse model, we will also examine other models. Where inconsistencies are identified among the studies, we attempt to determine whether such inconsistencies arise from methodological differences or alternative mechanisms. Ultimately, we address whether the allergen-exposed mouse is a suitable model for identifying promising new drugs for the treatment of human asthma. While a consensus is building that NO is beneficial or protective in subsets of asthmatics, results from studies using mouse models to investigate the individual roles of NO and the NOS enzymes in airway inflammation are often contradictory. Further research efforts with this model will allow us to distinguish which asthma patients may benefit best from NO donors and which may benefit from NO inhibitors.

Original languageEnglish (US)
Pages (from-to)2204-2213
Number of pages10
JournalCurrent Medicinal Chemistry
Volume14
Issue number20
DOIs
StatePublished - Aug 2007

Fingerprint

Nitric Oxide
Asthma
Inflammation
Nitric Oxide Synthase
Enzymes
Arginase
Lung
Nitric Oxide Donors
Ovalbumin
Practice Guidelines
Allergens
Animals
Animal Models
Tissue Donors
Clinical Trials
Research
Pharmaceutical Preparations

Keywords

  • Allergic asthma models
  • BALB/c mice
  • Inflammation
  • iNOS
  • L-arginine

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Mouse models of asthma : Can they give us mechanistic insights into the role of nitric oxide? / Mathrani, V. C.; Kenyon, Nicholas; Zeki, Amir; Last, Jerold A.

In: Current Medicinal Chemistry, Vol. 14, No. 20, 08.2007, p. 2204-2213.

Research output: Contribution to journalArticle

@article{2871ca001227425a838431352d7fa815,
title = "Mouse models of asthma: Can they give us mechanistic insights into the role of nitric oxide?",
abstract = "New clinical practice guidelines for patients with asthma include the recommendation to monitor exhaled breath nitric oxide (NO) levels. NO concentrations in exhaled breath are increased in asthmatics and increased NO levels correlate with worsening airway inflammation and asthma symptoms. The multiple roles of NO in the lung have not been delineated clearly. Clinical trials are being performed presently that test the apparently conflicting hypotheses that either donors or inhibitors of NO in the lung are effective strategies for treating asthma. These strategies evolved, in part, from results of pre-clinical studies performed in mice and other animal models. This review evaluates the existing literature with regard to mouse models of asthma and explores the often conflicting data on the role of NO, the nitric oxide synthase (NOS) enzymes, and the arginase enzymes in allergic airway inflammation. While we will emphasize the ovalbumin exposure mouse model, we will also examine other models. Where inconsistencies are identified among the studies, we attempt to determine whether such inconsistencies arise from methodological differences or alternative mechanisms. Ultimately, we address whether the allergen-exposed mouse is a suitable model for identifying promising new drugs for the treatment of human asthma. While a consensus is building that NO is beneficial or protective in subsets of asthmatics, results from studies using mouse models to investigate the individual roles of NO and the NOS enzymes in airway inflammation are often contradictory. Further research efforts with this model will allow us to distinguish which asthma patients may benefit best from NO donors and which may benefit from NO inhibitors.",
keywords = "Allergic asthma models, BALB/c mice, Inflammation, iNOS, L-arginine",
author = "Mathrani, {V. C.} and Nicholas Kenyon and Amir Zeki and Last, {Jerold A}",
year = "2007",
month = "8",
doi = "10.2174/092986707781389628",
language = "English (US)",
volume = "14",
pages = "2204--2213",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "20",

}

TY - JOUR

T1 - Mouse models of asthma

T2 - Can they give us mechanistic insights into the role of nitric oxide?

AU - Mathrani, V. C.

AU - Kenyon, Nicholas

AU - Zeki, Amir

AU - Last, Jerold A

PY - 2007/8

Y1 - 2007/8

N2 - New clinical practice guidelines for patients with asthma include the recommendation to monitor exhaled breath nitric oxide (NO) levels. NO concentrations in exhaled breath are increased in asthmatics and increased NO levels correlate with worsening airway inflammation and asthma symptoms. The multiple roles of NO in the lung have not been delineated clearly. Clinical trials are being performed presently that test the apparently conflicting hypotheses that either donors or inhibitors of NO in the lung are effective strategies for treating asthma. These strategies evolved, in part, from results of pre-clinical studies performed in mice and other animal models. This review evaluates the existing literature with regard to mouse models of asthma and explores the often conflicting data on the role of NO, the nitric oxide synthase (NOS) enzymes, and the arginase enzymes in allergic airway inflammation. While we will emphasize the ovalbumin exposure mouse model, we will also examine other models. Where inconsistencies are identified among the studies, we attempt to determine whether such inconsistencies arise from methodological differences or alternative mechanisms. Ultimately, we address whether the allergen-exposed mouse is a suitable model for identifying promising new drugs for the treatment of human asthma. While a consensus is building that NO is beneficial or protective in subsets of asthmatics, results from studies using mouse models to investigate the individual roles of NO and the NOS enzymes in airway inflammation are often contradictory. Further research efforts with this model will allow us to distinguish which asthma patients may benefit best from NO donors and which may benefit from NO inhibitors.

AB - New clinical practice guidelines for patients with asthma include the recommendation to monitor exhaled breath nitric oxide (NO) levels. NO concentrations in exhaled breath are increased in asthmatics and increased NO levels correlate with worsening airway inflammation and asthma symptoms. The multiple roles of NO in the lung have not been delineated clearly. Clinical trials are being performed presently that test the apparently conflicting hypotheses that either donors or inhibitors of NO in the lung are effective strategies for treating asthma. These strategies evolved, in part, from results of pre-clinical studies performed in mice and other animal models. This review evaluates the existing literature with regard to mouse models of asthma and explores the often conflicting data on the role of NO, the nitric oxide synthase (NOS) enzymes, and the arginase enzymes in allergic airway inflammation. While we will emphasize the ovalbumin exposure mouse model, we will also examine other models. Where inconsistencies are identified among the studies, we attempt to determine whether such inconsistencies arise from methodological differences or alternative mechanisms. Ultimately, we address whether the allergen-exposed mouse is a suitable model for identifying promising new drugs for the treatment of human asthma. While a consensus is building that NO is beneficial or protective in subsets of asthmatics, results from studies using mouse models to investigate the individual roles of NO and the NOS enzymes in airway inflammation are often contradictory. Further research efforts with this model will allow us to distinguish which asthma patients may benefit best from NO donors and which may benefit from NO inhibitors.

KW - Allergic asthma models

KW - BALB/c mice

KW - Inflammation

KW - iNOS

KW - L-arginine

UR - http://www.scopus.com/inward/record.url?scp=35348890158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348890158&partnerID=8YFLogxK

U2 - 10.2174/092986707781389628

DO - 10.2174/092986707781389628

M3 - Article

C2 - 17691958

AN - SCOPUS:35348890158

VL - 14

SP - 2204

EP - 2213

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 20

ER -